Review



panc 1  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC panc 1
    In vitro evaluation <t>of</t> <t>Panc-1</t> and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Panc 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 7966 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pmc13091541-179-56-61?v=ATCC
    Average 99 stars, based on 7966 article reviews
    panc 1 - by Bioz Stars, 2026-08
    99/100 stars

    Images

    1) Product Images from "Stromal homeostasis-restoring “rocket-like” nanomedicine inhibited pancreatic tumor growth in vivo"

    Article Title: Stromal homeostasis-restoring “rocket-like” nanomedicine inhibited pancreatic tumor growth in vivo

    Journal: Materials Today Bio

    doi: 10.1016/j.mtbio.2026.103014

    In vitro evaluation of Panc-1 and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Figure Legend Snippet: In vitro evaluation of Panc-1 and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Techniques Used: In Vitro, Colony Assay, Migration, Fluorescence, Cell Culture, Staining, Immunofluorescence, Standard Deviation



    Similar Products

    panc 1  (ATCC)
    99
    ATCC panc 1
    In vitro evaluation <t>of</t> <t>Panc-1</t> and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Panc 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pmc13091541-179-56-61?v=ATCC
    Average 99 stars, based on 1 article reviews
    panc 1 - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    86
    Procell Inc panc 1
    In vitro evaluation <t>of</t> <t>Panc-1</t> and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Panc 1, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pm42320116-189-23-6?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    panc 1 - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Procell Inc human pdac cell lines panc 1
    In vitro evaluation <t>of</t> <t>Panc-1</t> and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Human Pdac Cell Lines Panc 1, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pm42251943-52-1-39?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    human pdac cell lines panc 1 - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    96
    ATCC panc10 05
    ( A ) Clonogenic survival with increased number of CRISPR/Cas9 target sites in the human genome of 2 PC cell lines. Number of target sites in parentheses; “rep” indicates repetitive element-targeting. N = 3; mean ± SEM, normalized to NT. ( B ) Cell survival with increased number of CRISPR/Cas9 target sites as detected by alamar blue cell viability assay. N = 3; mean ± SEM, normalized to NT. ( C ) Representative images of γH2A.X staining <t>in</t> <t>Panc10.05</t> cells transduced with NT or 715F(5) or 230F(12) multitarget sgRNAs. Images at 40× original magnification; scale bar is 5 μm. N = 3. ( D ) Number of γH2A.X foci as a function of the number of CRISPR/Cas9 target sites. >100 nuclei were analyzed for each condition. Dunnett’s test between NT and each multitarget sgRNA; *** P < 0.001, **** P < 0.0001. N = 3; mean ± SEM. ( E ) Clonogenic and cell survival 21 days after electroporating in CRISPR/Cas9 with multitarget sgRNAs or a pool of 5 sgRNAs targeting different noncoding mutations in the Panc10.05 genome. N = 2/3; mean ± SEM, normalized to NT.
    Panc10 05, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pmc13178663-284-4-8?v=ATCC
    Average 96 stars, based on 1 article reviews
    panc10 05 - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    99
    ATCC experimental models u2 os ecacc 92022711 panc 1 ecacc
    ( A ) Clonogenic survival with increased number of CRISPR/Cas9 target sites in the human genome of 2 PC cell lines. Number of target sites in parentheses; “rep” indicates repetitive element-targeting. N = 3; mean ± SEM, normalized to NT. ( B ) Cell survival with increased number of CRISPR/Cas9 target sites as detected by alamar blue cell viability assay. N = 3; mean ± SEM, normalized to NT. ( C ) Representative images of γH2A.X staining <t>in</t> <t>Panc10.05</t> cells transduced with NT or 715F(5) or 230F(12) multitarget sgRNAs. Images at 40× original magnification; scale bar is 5 μm. N = 3. ( D ) Number of γH2A.X foci as a function of the number of CRISPR/Cas9 target sites. >100 nuclei were analyzed for each condition. Dunnett’s test between NT and each multitarget sgRNA; *** P < 0.001, **** P < 0.0001. N = 3; mean ± SEM. ( E ) Clonogenic and cell survival 21 days after electroporating in CRISPR/Cas9 with multitarget sgRNAs or a pool of 5 sgRNAs targeting different noncoding mutations in the Panc10.05 genome. N = 2/3; mean ± SEM, normalized to NT.
    Experimental Models U2 Os Ecacc 92022711 Panc 1 Ecacc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pm42129541-292-12-42?v=ATCC
    Average 99 stars, based on 1 article reviews
    experimental models u2 os ecacc 92022711 panc 1 ecacc - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    86
    Procell Inc panc 0813
    ( A ) Clonogenic survival with increased number of CRISPR/Cas9 target sites in the human genome of 2 PC cell lines. Number of target sites in parentheses; “rep” indicates repetitive element-targeting. N = 3; mean ± SEM, normalized to NT. ( B ) Cell survival with increased number of CRISPR/Cas9 target sites as detected by alamar blue cell viability assay. N = 3; mean ± SEM, normalized to NT. ( C ) Representative images of γH2A.X staining <t>in</t> <t>Panc10.05</t> cells transduced with NT or 715F(5) or 230F(12) multitarget sgRNAs. Images at 40× original magnification; scale bar is 5 μm. N = 3. ( D ) Number of γH2A.X foci as a function of the number of CRISPR/Cas9 target sites. >100 nuclei were analyzed for each condition. Dunnett’s test between NT and each multitarget sgRNA; *** P < 0.001, **** P < 0.0001. N = 3; mean ± SEM. ( E ) Clonogenic and cell survival 21 days after electroporating in CRISPR/Cas9 with multitarget sgRNAs or a pool of 5 sgRNAs targeting different noncoding mutations in the Panc10.05 genome. N = 2/3; mean ± SEM, normalized to NT.
    Panc 0813, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pm42129298-332-9-23?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    panc 0813 - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Procell Inc panc 1 cell lines
    ( A ) Clonogenic survival with increased number of CRISPR/Cas9 target sites in the human genome of 2 PC cell lines. Number of target sites in parentheses; “rep” indicates repetitive element-targeting. N = 3; mean ± SEM, normalized to NT. ( B ) Cell survival with increased number of CRISPR/Cas9 target sites as detected by alamar blue cell viability assay. N = 3; mean ± SEM, normalized to NT. ( C ) Representative images of γH2A.X staining <t>in</t> <t>Panc10.05</t> cells transduced with NT or 715F(5) or 230F(12) multitarget sgRNAs. Images at 40× original magnification; scale bar is 5 μm. N = 3. ( D ) Number of γH2A.X foci as a function of the number of CRISPR/Cas9 target sites. >100 nuclei were analyzed for each condition. Dunnett’s test between NT and each multitarget sgRNA; *** P < 0.001, **** P < 0.0001. N = 3; mean ± SEM. ( E ) Clonogenic and cell survival 21 days after electroporating in CRISPR/Cas9 with multitarget sgRNAs or a pool of 5 sgRNAs targeting different noncoding mutations in the Panc10.05 genome. N = 2/3; mean ± SEM, normalized to NT.
    Panc 1 Cell Lines, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/panc/pm42129298-332-12-23?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    panc 1 cell lines - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    Image Search Results


    In vitro evaluation of Panc-1 and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Materials Today Bio

    Article Title: Stromal homeostasis-restoring “rocket-like” nanomedicine inhibited pancreatic tumor growth in vivo

    doi: 10.1016/j.mtbio.2026.103014

    Figure Lengend Snippet: In vitro evaluation of Panc-1 and Pan02 cells after different treatments. (A) Colony formation assay of Panc-1 and Pan02 cells after different treatments. (B) Quantification of colony numbers of Panc-1 and Pan02 cells under the indicated treatments. (C) Representative images of cell migration of Panc-1 and Pan02 cells after different treatments. (D) Quantification of residual area of Panc-1 and Pan02 cells in each group. (E) ROS fluorescence intensity of Panc-1 cells after different treatments. (F) ROS fluorescence intensity of Pan02 cells after different treatments. (G) Viability of Panc-1 cells co-cultured with L929 cells in a transwell system after different treatments. (H) Viability of Pan02 cells co-cultured with L929 cells in a transwell system after different treatments. (I) Representative CLSM images of Panc-1 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups (scale bar: 200 μm). (J) Representative CLSM images of Pan02 cells co-stained with Calcein-AM (green) and PI (red) after treatment with different groups. (K) Immunofluorescence staining of uPA in Panc-1 cells after different treatments.(scale bar:100 μm). (L) Immunofluorescence staining of uPA in Pan02 cells after different treatments. Data are presented as mean ± standard deviation (SD), n = 3. Statistical significance was analyzed by one-way ANOVA with t -test; ns, not significant; ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: Triethylamine (TEA, Sigma-Aldrich); Cetyltrimethylammonium bromide (CTAB, Xinyanbomei); Sodium salicylate (NaSal, Sigma-Aldrich); Tetraethyl orthosilicate (TEOS, CATO); 1,2-Bis(triethoxysilyl)ethane (BTES, Xinhengyan); Ethanol; Hydrochloric acid; Methanol; Gemcitabine (MedChemExpress); Ammonium bicarbonate (Coolaber); Urokinase-type plasminogen activator (Solarbio); CCK-8 kit (CWBIO); ROS staining kit (Poolyue); Calcein-AM/PI kit (DOJINDO); anti-uPA antibody (HUABIO); Calcium chloride (Supelco); Indocyanine green (zrbiorise); Dulbecco's modified Eagle medium (DMEM, Sigma-Aldrich); Panc-1, Pan02, and L929 cells (ATCC); Fluorescein isothiocyanate (FITC, Qisong); 4′,6-diamidino-2-phenylindole (DAPI, Solarbio); DUTP (Roche); IPR-803 (MCE).

    Techniques: In Vitro, Colony Assay, Migration, Fluorescence, Cell Culture, Staining, Immunofluorescence, Standard Deviation

    ( A ) Clonogenic survival with increased number of CRISPR/Cas9 target sites in the human genome of 2 PC cell lines. Number of target sites in parentheses; “rep” indicates repetitive element-targeting. N = 3; mean ± SEM, normalized to NT. ( B ) Cell survival with increased number of CRISPR/Cas9 target sites as detected by alamar blue cell viability assay. N = 3; mean ± SEM, normalized to NT. ( C ) Representative images of γH2A.X staining in Panc10.05 cells transduced with NT or 715F(5) or 230F(12) multitarget sgRNAs. Images at 40× original magnification; scale bar is 5 μm. N = 3. ( D ) Number of γH2A.X foci as a function of the number of CRISPR/Cas9 target sites. >100 nuclei were analyzed for each condition. Dunnett’s test between NT and each multitarget sgRNA; *** P < 0.001, **** P < 0.0001. N = 3; mean ± SEM. ( E ) Clonogenic and cell survival 21 days after electroporating in CRISPR/Cas9 with multitarget sgRNAs or a pool of 5 sgRNAs targeting different noncoding mutations in the Panc10.05 genome. N = 2/3; mean ± SEM, normalized to NT.

    Journal: The Journal of Clinical Investigation

    Article Title: Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer

    doi: 10.1172/JCI190121

    Figure Lengend Snippet: ( A ) Clonogenic survival with increased number of CRISPR/Cas9 target sites in the human genome of 2 PC cell lines. Number of target sites in parentheses; “rep” indicates repetitive element-targeting. N = 3; mean ± SEM, normalized to NT. ( B ) Cell survival with increased number of CRISPR/Cas9 target sites as detected by alamar blue cell viability assay. N = 3; mean ± SEM, normalized to NT. ( C ) Representative images of γH2A.X staining in Panc10.05 cells transduced with NT or 715F(5) or 230F(12) multitarget sgRNAs. Images at 40× original magnification; scale bar is 5 μm. N = 3. ( D ) Number of γH2A.X foci as a function of the number of CRISPR/Cas9 target sites. >100 nuclei were analyzed for each condition. Dunnett’s test between NT and each multitarget sgRNA; *** P < 0.001, **** P < 0.0001. N = 3; mean ± SEM. ( E ) Clonogenic and cell survival 21 days after electroporating in CRISPR/Cas9 with multitarget sgRNAs or a pool of 5 sgRNAs targeting different noncoding mutations in the Panc10.05 genome. N = 2/3; mean ± SEM, normalized to NT.

    Article Snippet: With the exception of Panc10.05, which is an ATCC line, all other cell lines and their derivatives (including Panc10.05-derived lines) are available through Material Transfer Agreements.

    Techniques: CRISPR, Viability Assay, Staining, Transduction

    ( A – C ) Tumor growth experiment in subcutaneous xenograft models. Panc10.05 Cas9-expressing cells transduced with the following sgRNAs: NT, 715F(5), 230F(12), or a pool of 9 sgRNAs targeting different noncoding mutations unique to Panc10.05 (Panc10.05 pool) were injected into nude mice for tumor growth. ( A ) Percentage of tumors present postxenograft. # indicates absence of 2 data points due to early death around week 5 (33–36 days). ( B ) Tumor volume measurements postxenograft. Dunn-Šidák test between NT and the other treatment groups on week 6, all **** P < 0.0001. N = 10; mean ± SEM. & indicates absence of week 5 and 6 data points of 2 tumors due to early death. $ indicates absence of 2 data points from week 6 due to early death. ( C ) Tumor weight measurements on week 6 postxenograft. Dunnett’s test between NT ( N = 8) and 715F(5): P = 0.0003 ( N = 8), 230F(12): P = 0.0008 ( N = 10), and Panc10.05 pool: P = 0.0004 ( N = 10). *** P < 0.001. Mean ± SEM was shown. ( D and E ) Metastatic growth experiment in hemispleen injection mouse models of liver metastasis. Hematoxylin and eosin (H&E) staining of the liver sections of mice treated with ( D ) NT ( N = 7) or ( E ) 230F(12) ( N = 5) sgRNA-expressing PC cells. Black arrow: tumor growth; green arrow: tumor regression. The top and bottom panels represent liver sections from 2 different mice of the same treatment group. Images at 20× original magnification; scale bar is 100 μm.

    Journal: The Journal of Clinical Investigation

    Article Title: Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer

    doi: 10.1172/JCI190121

    Figure Lengend Snippet: ( A – C ) Tumor growth experiment in subcutaneous xenograft models. Panc10.05 Cas9-expressing cells transduced with the following sgRNAs: NT, 715F(5), 230F(12), or a pool of 9 sgRNAs targeting different noncoding mutations unique to Panc10.05 (Panc10.05 pool) were injected into nude mice for tumor growth. ( A ) Percentage of tumors present postxenograft. # indicates absence of 2 data points due to early death around week 5 (33–36 days). ( B ) Tumor volume measurements postxenograft. Dunn-Šidák test between NT and the other treatment groups on week 6, all **** P < 0.0001. N = 10; mean ± SEM. & indicates absence of week 5 and 6 data points of 2 tumors due to early death. $ indicates absence of 2 data points from week 6 due to early death. ( C ) Tumor weight measurements on week 6 postxenograft. Dunnett’s test between NT ( N = 8) and 715F(5): P = 0.0003 ( N = 8), 230F(12): P = 0.0008 ( N = 10), and Panc10.05 pool: P = 0.0004 ( N = 10). *** P < 0.001. Mean ± SEM was shown. ( D and E ) Metastatic growth experiment in hemispleen injection mouse models of liver metastasis. Hematoxylin and eosin (H&E) staining of the liver sections of mice treated with ( D ) NT ( N = 7) or ( E ) 230F(12) ( N = 5) sgRNA-expressing PC cells. Black arrow: tumor growth; green arrow: tumor regression. The top and bottom panels represent liver sections from 2 different mice of the same treatment group. Images at 20× original magnification; scale bar is 100 μm.

    Article Snippet: With the exception of Panc10.05, which is an ATCC line, all other cell lines and their derivatives (including Panc10.05-derived lines) are available through Material Transfer Agreements.

    Techniques: Expressing, Transduction, Injection, Staining

    ( A ) Analysis workflow for quantification of on- and off-target sites in resistant colonies from clonogenicity assays. ( B and C ) Comparisons of mutation frequency at 1–2 mismatch (mm) sites detected by WGS and targeted deep NGS in resistant colonies. ( B ) 531F(2) sgRNA–resistant colonies. Four 1 mm sites were sequenced using the same primers. N = 2, mean ± SEM. ( C ) Panc10.05 164R(14) sgRNA–resistant colony. Noncanonical PAMs were indicated in parentheses. N = 1. ( D ) Fold-change of multitarget sgRNAs in 2 PC cell lines 21 days after transduction. Number of target sites in parentheses; “rep” indicates repetitive element targeting. N = 3; mean ± SEM. ( E ) sgRNA tag survival over time. N = 3; mean ± SEM. ( F ) Mutation frequencies of eight 164R(14) sgRNA target sites in Panc10.05 Cas9-expressing cells at various time points. N = 3; mean ± SEM. Bell-shaped least squares regression; R 2 = 0.60–0.74. Relatively low percentages were due to the absence of antibiotic selection of transduced cells.

    Journal: The Journal of Clinical Investigation

    Article Title: Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer

    doi: 10.1172/JCI190121

    Figure Lengend Snippet: ( A ) Analysis workflow for quantification of on- and off-target sites in resistant colonies from clonogenicity assays. ( B and C ) Comparisons of mutation frequency at 1–2 mismatch (mm) sites detected by WGS and targeted deep NGS in resistant colonies. ( B ) 531F(2) sgRNA–resistant colonies. Four 1 mm sites were sequenced using the same primers. N = 2, mean ± SEM. ( C ) Panc10.05 164R(14) sgRNA–resistant colony. Noncanonical PAMs were indicated in parentheses. N = 1. ( D ) Fold-change of multitarget sgRNAs in 2 PC cell lines 21 days after transduction. Number of target sites in parentheses; “rep” indicates repetitive element targeting. N = 3; mean ± SEM. ( E ) sgRNA tag survival over time. N = 3; mean ± SEM. ( F ) Mutation frequencies of eight 164R(14) sgRNA target sites in Panc10.05 Cas9-expressing cells at various time points. N = 3; mean ± SEM. Bell-shaped least squares regression; R 2 = 0.60–0.74. Relatively low percentages were due to the absence of antibiotic selection of transduced cells.

    Article Snippet: With the exception of Panc10.05, which is an ATCC line, all other cell lines and their derivatives (including Panc10.05-derived lines) are available through Material Transfer Agreements.

    Techniques: Mutagenesis, Transduction, Expressing, Selection

    ( A – C ) TS0111 Cas9-expressing cells were transduced with 164R(14) sgRNA and subjected to break-apart FISH assays. ( A ) Break-apart FISH strategy at the 1q41 cut site. Abnormal FISH patterns were shown using cells collected at early time points. DNA was stained with DAPI. N = 1. ( B ) Complex rearrangements were observed in cells 14 and 16 days after transduction. N = 1. ( C ) Percentage of cells with rearrangements at 1q41 detected by break-apart FISH assay over time. ( D ) Shown are Panc10.05 cells transduced with NT2 or 164R(14) and stained with wheat germ agglutinin (WGA; green) and Hoechst 33342 (blue) 14 days after transduction. White arrow: large nucleus; yellow arrows: multiple nuclei in a cell. N = 3. ( E ) Number of TS0111-transduced cells with >6 X chromosomes over time using XY FISH. ( F ) Apoptosis analysis of Panc10.05 cells after treatment with 164R(14) or NT2 using annexin V flow cytometry assay. Šidák’s multiple comparisons test, day 7: ** P = 0.005, day 14: *** P = 0.0008, and day 21: P = 0.53. N = 3; mean ± SEM.

    Journal: The Journal of Clinical Investigation

    Article Title: Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer

    doi: 10.1172/JCI190121

    Figure Lengend Snippet: ( A – C ) TS0111 Cas9-expressing cells were transduced with 164R(14) sgRNA and subjected to break-apart FISH assays. ( A ) Break-apart FISH strategy at the 1q41 cut site. Abnormal FISH patterns were shown using cells collected at early time points. DNA was stained with DAPI. N = 1. ( B ) Complex rearrangements were observed in cells 14 and 16 days after transduction. N = 1. ( C ) Percentage of cells with rearrangements at 1q41 detected by break-apart FISH assay over time. ( D ) Shown are Panc10.05 cells transduced with NT2 or 164R(14) and stained with wheat germ agglutinin (WGA; green) and Hoechst 33342 (blue) 14 days after transduction. White arrow: large nucleus; yellow arrows: multiple nuclei in a cell. N = 3. ( E ) Number of TS0111-transduced cells with >6 X chromosomes over time using XY FISH. ( F ) Apoptosis analysis of Panc10.05 cells after treatment with 164R(14) or NT2 using annexin V flow cytometry assay. Šidák’s multiple comparisons test, day 7: ** P = 0.005, day 14: *** P = 0.0008, and day 21: P = 0.53. N = 3; mean ± SEM.

    Article Snippet: With the exception of Panc10.05, which is an ATCC line, all other cell lines and their derivatives (including Panc10.05-derived lines) are available through Material Transfer Agreements.

    Techniques: Expressing, Transduction, Staining, Flow Cytometry

    ( A ) SVs were categorized by whether the breakpoints resulted from noninduced DSBs (0-target SV), from 1 site that was CRISPR/Cas9 targeted (1-target SV), or from both sites being targeted (2-target SV). ( B ) Quantification of SVs through WGS analyses of Panc10.05 surviving/resistant colonies after treatment with multitarget sgRNAs. N = 2 except for 164R(14) ( N = 1); mean ± SEM. ( C ) Number of translocations detected in each Panc10.05 surviving colony. N = 2 except for 164R(14) ( N = 1); mean ± SEM. ( D ) Sequences at breakpoint junctions were analyzed to identify indels and microhomology sequences (mh). Shown are the percentages of breakpoint types in each surviving colony. N = 2 except for 164R(14) ( N = 1); mean only. ( E ) Example of a 0-target deletion from a 715F(5) sgRNA–resistant colony. The red dotted lines indicate the 3 bp homology region on both upstream and downstream sequences.

    Journal: The Journal of Clinical Investigation

    Article Title: Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer

    doi: 10.1172/JCI190121

    Figure Lengend Snippet: ( A ) SVs were categorized by whether the breakpoints resulted from noninduced DSBs (0-target SV), from 1 site that was CRISPR/Cas9 targeted (1-target SV), or from both sites being targeted (2-target SV). ( B ) Quantification of SVs through WGS analyses of Panc10.05 surviving/resistant colonies after treatment with multitarget sgRNAs. N = 2 except for 164R(14) ( N = 1); mean ± SEM. ( C ) Number of translocations detected in each Panc10.05 surviving colony. N = 2 except for 164R(14) ( N = 1); mean ± SEM. ( D ) Sequences at breakpoint junctions were analyzed to identify indels and microhomology sequences (mh). Shown are the percentages of breakpoint types in each surviving colony. N = 2 except for 164R(14) ( N = 1); mean only. ( E ) Example of a 0-target deletion from a 715F(5) sgRNA–resistant colony. The red dotted lines indicate the 3 bp homology region on both upstream and downstream sequences.

    Article Snippet: With the exception of Panc10.05, which is an ATCC line, all other cell lines and their derivatives (including Panc10.05-derived lines) are available through Material Transfer Agreements.

    Techniques: CRISPR

    ( A ) Mutation frequency of sgRNA target sites in each CRISPR/Cas9 surviving colony used for xenograft experiment. ( B – D ) Tumor growth experiment of CRISPR/Cas9 surviving colonies in subcutaneous xenograft models. In addition to a nontransduced cell line (NTC), surviving colonies from clonogenicity experiment transduced with NT sgRNA (NT colony #1 and NT colony #2) and multitarget sgRNAs 531F(2), 715F(5), and 551R(8) were injected into nude mice for tumor growth. ( B ) Tumor volume measurements postxenograft. Dunnett’s test between NTC and NT #1: P = 0.050, NT #2: P = 0.145, 531F(2): P = 0.349, 715F(5): P = 0.0002, 551R(8): P = 0.498 on week 5. N = 10 ( N = 8 for NTC on day 30 and 33 due to early death); mean ± SEM. ( C ) Tumor weight measurements. Dunnett’s test between NTC and NT #1: P = 0.341, NT #2: P = 0.437, 531F(2): P = 0.457, 715F(5): P = 0.041, and 551R(8): P = 0.531. N = 10; mean ± SEM. ( D ) Body weight of mice 5 weeks postxenograft. Dunn-Šidák test between NTC and the other treatment groups showed no significant differences. N = 5 except for NTC ( N = 4 due to early death); mean ± SEM. ( E ) Cell survival of Panc10.05 551R(8)–resistant colony that was retransduced with nontargeting sgRNA (NT2) or multitargeting sgRNAs — 551R(8), 230F(12), and 164R(14) — as detected by alamar blue cell viability assay and normalized to NT2. N = 3; mean ± SEM. ( F ) Cell survival of TS0111- and Panc10.05 715F(5)–resistant colony that was retransduced with nontargeting sgRNA (NT2) or multitargeting sgRNAs — 715F(5), 230F(12), and 164R(14) — as detected by alamar blue cell viability assay and normalized to NT2. N = 3; mean ± SEM.

    Journal: The Journal of Clinical Investigation

    Article Title: Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer

    doi: 10.1172/JCI190121

    Figure Lengend Snippet: ( A ) Mutation frequency of sgRNA target sites in each CRISPR/Cas9 surviving colony used for xenograft experiment. ( B – D ) Tumor growth experiment of CRISPR/Cas9 surviving colonies in subcutaneous xenograft models. In addition to a nontransduced cell line (NTC), surviving colonies from clonogenicity experiment transduced with NT sgRNA (NT colony #1 and NT colony #2) and multitarget sgRNAs 531F(2), 715F(5), and 551R(8) were injected into nude mice for tumor growth. ( B ) Tumor volume measurements postxenograft. Dunnett’s test between NTC and NT #1: P = 0.050, NT #2: P = 0.145, 531F(2): P = 0.349, 715F(5): P = 0.0002, 551R(8): P = 0.498 on week 5. N = 10 ( N = 8 for NTC on day 30 and 33 due to early death); mean ± SEM. ( C ) Tumor weight measurements. Dunnett’s test between NTC and NT #1: P = 0.341, NT #2: P = 0.437, 531F(2): P = 0.457, 715F(5): P = 0.041, and 551R(8): P = 0.531. N = 10; mean ± SEM. ( D ) Body weight of mice 5 weeks postxenograft. Dunn-Šidák test between NTC and the other treatment groups showed no significant differences. N = 5 except for NTC ( N = 4 due to early death); mean ± SEM. ( E ) Cell survival of Panc10.05 551R(8)–resistant colony that was retransduced with nontargeting sgRNA (NT2) or multitargeting sgRNAs — 551R(8), 230F(12), and 164R(14) — as detected by alamar blue cell viability assay and normalized to NT2. N = 3; mean ± SEM. ( F ) Cell survival of TS0111- and Panc10.05 715F(5)–resistant colony that was retransduced with nontargeting sgRNA (NT2) or multitargeting sgRNAs — 715F(5), 230F(12), and 164R(14) — as detected by alamar blue cell viability assay and normalized to NT2. N = 3; mean ± SEM.

    Article Snippet: With the exception of Panc10.05, which is an ATCC line, all other cell lines and their derivatives (including Panc10.05-derived lines) are available through Material Transfer Agreements.

    Techniques: Mutagenesis, CRISPR, Transduction, Injection, Viability Assay